In contrast to our results, they noted that after a follow-up of 10 months, there were no significant survival differences between HER2-low and HER2-zero early-stage breast cancer when stratified based on HR status and after adjusting for the confounders [37]. Here, ERBB2 is linked to breast carcinoma.